MANZO PHARMACEUTICALS, INC. Inactive Instrument
Manzo Pharmaceuticals, Inc. Share Price Other OTC
Equities
MNZO
US56510D1063
Pharmaceuticals
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2003 | 3M 251M | Sales 2004 | 3.07M 256M | Capitalization | 8.07K 674K |
|---|---|---|---|---|---|
| Net income 2003 | -3M -250M | Net income 2004 | -4M -334M | EV / Sales 2003 | - |
| Net Debt 2003 | 7.3 609.58 | Net Debt 2004 | 6.51 543.65 | EV / Sales 2004 | - |
| P/E ratio 2003 |
-0.73
x | P/E ratio 2004 |
-0.42
x | Employees | - |
| Yield 2003 * |
-
| Yield 2004 |
-
| Free-Float | 0% |
More Fundamentals
* Assessed data
More news
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | - |
Manzo Pharmaceuticals, Inc. is a biotechnology company that manufactures and sells products and owns patents in the field of supplemental and holistic cures sold through retail and online distribution. The Company also develops its lactose intolerance product, in which it holds an exclusive patent license. The Company's primary products are dietary supplements, probiotics and natural remedies. The Company's subsidiary, Manzo Pharmaceuticals LLC (Manzo), is an alternative healthcare company with patents for a probiotic remedy for lactose intolerance. The Company also owns other products, including a remedy for babies suffering from colic and/or digestive gas. Manzo's Lacto-Freedom probiotic is a probiotic that aids in the digestion of lactose containing foods, designed specifically for people with lactose sensitivity.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| +13.14% | 9.3B | |
| -13.75% | 5.01B | |
| +41.51% | 4.47B | |
| +4.51% | 3.96B | |
| +21.10% | 2.44B | |
| -15.23% | 2.41B | |
| -25.12% | 2.23B | |
| +19.51% | 2.02B | |
| +5.11% | 1.69B |
